ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 80%
Go here to see the original:
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Recommendation and review posted by G. Smith
